Immuron shares soar more than 20%
Immuron Ltd (ASX:IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens released extremely promising clinical results on Wednesday, resulting in the company’s shares surging more than 20%.
The positive results related to a recent study on the immuno-reactivity of its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan® to infectious Vibrio cholera strains from South-East Asia.
Sponsored by the US Department of Defence and funded through the Defence Health Agency, the study was performed at the Department of Enteric Diseases (DED), Armed Forces Research Institute of Medical Sciences (AFRIMS), an overseas laboratory of the Walter Reed Army Institute of Research (WRAIR) located in Bangkok, Thailand.
Expanding the extent of Travelan® applications
The goal was to investigate the breadth of Travelan®‘s immunological reactivity against pathogenic Vibrio cholera bacterial isolates.
Clinical isolates were collected from infected personnel located in Bangladesh, Cambodia, and Thailand, enabling researchers to gauge Travelan®‘s potential against bacterial strains typically seen in the field.
When compared to a placebo control, researchers found that the polyclonal antibodies comprising Immuron’s Travelan® product were reactive to all 71 clinical isolates from these infected individuals.
The ability of Travelan® to bind these bacteria highlights the broad-spectrum recognition by Travelan® of surface antigens on potentially debilitating and even life-threatening bacteria.
Positive impact on corporate profile
Immuron’s share price has surged on the back of this news, and Chief Executive Gary Jacob commented on broader investor sentiment in saying, “The response we have recently received from the investment community to our collaboration with the US Department of Defence has been quite extraordinary, and in my opinion, this is indicative of the high significance the investment community places on this collaborative effort.”
With regard to the impact these developments have on potential applications of Travelan®, Jacob said, “The work completed by our research collaborators at the WRAIR has provided the company with a comprehensive characterisation profile of our flagship product which clearly demonstrates the potential effectiveness of Travelan® and the Immuron technology platform to neutralise pathogenic gastrointestinal bacterial infections, and offers significant potential as a preventive treatment for US military personnel and civilians stationed or traveling in locations where such infections may be debilitating.”
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.